LA FERLA BARBARA

Zerbato, B., Brancato, V., Giampà, M., Taverna, G., Monterosso, G., Taglietti, L., et al. (2025). Hexosamine Pathway inhibition: one molecule able to induce a Brcaness phenotype as promising cancer therapy. Intervento presentato a: BtBs day 2025 – Giornata del Dipartimento di Biotecnologie e Bioscienze - UNIMIB, University of Milano-Bicocca, Milan, Italy. Detail

Zerbato, B., Brancato, V., Giampà, M., Taverna, G., Monterosso, G., Taglietti, L., et al. (2025). PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells. Intervento presentato a: 63th SIB Congress - September 10-12, 2025, Palermo, Italy. Detail

Zerbato, B., Brancato, V., Giampà, M., Taverna, G., Monterosso, G., Taglietti, L., et al. (2025). Hexosamine Biosynthetic Pathway inhibition sensitizes pancreatic cancer cells to DNA damage. Intervento presentato a: Cancer Research Day - Syöpätutkimuspäivä 2025 - 12.3.2025, Tampere, Finland. Detail

Taglietti, L., Bonapace, G., Clemente, F., Legnani, L., Moricca, M., Mangiatordi, G., et al. (2025). L-Iduronic Acid-Type 1-N-Iminosugars as Pharmacological Chaperones for the Rescue of α-L-Iduronidase in Mucopolysaccharidosis Type I. Intervento presentato a: XIX Convegno-Scuola Sulla Chimica dei Carboidrati (XIX CSCC 2025), Pontignano (SI), Italy. Detail

Zerbato, B., Brancato, V., Giampà, M., Taverna, G., Monterosso, G., Taglietti, L., et al. (2025). PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells. Intervento presentato a: 17th PhD meeting TeCSBi, University of Milano-Bicocca, Milan, Italy. Detail